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ABSTRACT
Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. 
However, new treatment modalities and novel drugs have been introduced and 
thus additional tools for therapy monitoring are increasingly needed. Therefore, we 
evaluated the radiotracers 11C-Methionine (paraprotein-biosynthesis) and 18F-FDG 
(glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome 
prediction. Influence of proteasome-inhibition on radiotracer-uptake of different 
MM cell-lines and patient-derived CD138+ plasma cells was analyzed and related to 
tumor-biology. Mice xenotransplanted with MM.1S tumors underwent MET- and FDG-
μPET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment 
with bortezomib were correlated to survival. Treatment reduced both MET and 
FDG uptake; changes in tracer-retention correlated with a switch from high to low 
CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 
30–79% as early as 24 h after bortezomib injection. No significant differences were 
detected thus early with FDG. This finding was confirmed in patient-derived MM cells. 
Importantly, early reduction of MET- but not FDG-uptake correlated with improved 
survival and reduced tumor burden in mice. Our results suggest that MET is superior 
to FDG in very early assessment of response to anti-myeloma-therapy. Early changes 
in MET-uptake have predictive potential regarding response and survival. MET-PET 
holds promise to individualize therapies in MM in future.
INTRODUCTION
Multiple myeloma (MM) is a hematological 
malignancy arising from clonal expansion of post 
germinal center B cells (plasma cells). These B cells 
are characterized by markedly increased production of 
aberrant immunoglobulins (Ig; M-protein), which are 
secreted but also accumulate intracellularly. Although 
recent years have brought great progress in terms of 
treatment options including reversible and non-reversible 
proteasome inhibitors (e.g. bortezomib, carfilzomib 
and ixazomib), immunomodulatory drugs (e.g. 
thalidomide, lenalidomide and pomalidomide) or stem 
cell transplantation, almost all MM patients relapse (1,2). 
Thus, MM remains an essentially non-curable disease, 
at least partly due to striking inter- and intra-patient 
heterogeneity involving multiple MM clones and rapid 
evolution of resistance (3,4).
The role of imaging in MM remains to be clarified. 
Current diagnostic and staging strategies rely on structural 
imaging techniques such as whole body X-ray or computed 
tomography (CT). Both modalities aim at the detection of 
anatomical lesions, but fail to give information on disease 
activity. Thus, they are not suitable to monitor treatment 
response. Several studies have shown the usefulness of 
molecular imaging techniques such as positron emission 
tomography (PET) or PET/CT using the radiolabeled 
glucose analog 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) 
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for diagnosis, staging and prognostication of MM, leading 
to its implementation into the Durie/Salmon PLUS staging 
system (5–11). In addition, PET/CT was recently reported 
to be a very useful tool for monitoring of anti-myeloma 
therapy (12). However, reduced sensitivity and specificity 
of FDG (e.g. diffuse bone marrow infiltrations [false 
negative] or inflammatory lesions [false positive]) has 
been reported (13). In order to improve and individualize 
patient management, there is clearly a need to develop 
and validate novel tracers. Requirements for an ‘ideal’ 
tracer would include its ability: to differentiate between 
active and non-active MM manifestations (both intra- and 
extramedullary lesions); importantly, to provide a link to 
the underlying biology and/or metabolism; to depict tumor 
heterogeneity and/or to identify MM subtypes; to allow for 
an early diagnosis and to monitor response to therapy as 
early as possible.
We previously demonstrated a significantly higher 
retention of the radiolabeled amino acid L-methyl-[11C]-
methionine (11C-MET) and an association of MET-
uptake with Ig light chain levels in biologically diverse 
myeloma cell lines and patient-derived CD138+-plasma 
cells (14). This study aimed at the in vivo validation of 
MET as radiotracer and biomarker for MM. In addition, 
the versatility of MET and FDG for monitoring treatment 
response to different proteasome inhibitors was assessed 
in human MM cell lines, primary patient-derived CD138+-
plasma cells and xenografted mice. Lastly, the predictive 
potential of these radiotracers regarding response and 
survival was assessed.
RESULTS
Monitoring response to proteasome inhibitors in 
MM cell lines using MET or FDG
To evaluate the suitability of MET and FDG for 
monitoring response to anti-MM therapy, MM cell lines 
were treated with either of three proteasome inhibitors, 
bortezomib (Bz; Velcade®), ixazomib (Iz; MLN9708) or 
carfilzomib (Cz; Kyprolis®). 48 h after drug addition, the 
capacity to store MET or FDG, respectively, was assessed 
in uptake experiments. In agreement with our previously 
published data (14), MET uptake in untreated control cells 
was higher than that of FDG. Comparing untreated with 
treated cells, a significant reduction in tracer-retention 
could be observed for all treatments at any time points 
analyzed with remaining MET-uptake slightly higher than 
that of FDG (Figure 1).
Changes in tracer uptake upon proteasome 
inhibition are associated with CD138 cell 
surface levels
Analysis of the MM marker and adhesion molecule 
CD138 at the cell surface demonstrated an almost identical 
fraction of CD138 expressing cells following incubation 
with either proteasome inhibitor (Bz, Cz, Iz) when 
compared to untreated controls (Figure 2A). However, 
the extent of CD138 expression was significantly reduced 
(p < 0.02) (Figure 2B); a more detailed evaluation 
revealed that the ratio of CD138high to CD138low MM 
cells reversed (Figure 2C). This reversal was positively 
associated with radiotracer uptake: the larger the reduction 
in tracer uptake, the less CD138 was present at the cell 
surface of MM cell lines (Supplementary Figure 1A; see 
the Supplemental Data Set link at the top of the online 
article). Results from ELISA-assays suggested that the 
loss could only in part be explained by enhanced shedding 
of CD138: while the amount of CD138 in the medium of 
OPM-2 cells treated with Bz increased 2-fold (compared 
to untreated cells), it was about the same in MM.1S and 
half as much in INA-6 (Supplementary Figure 2).
Treatment-induced alterations of further 
hallmarks of MM biology do not parallel 
changes in tracer uptake
MM diagnosis and follow-up include analysis of 
various markers, including levels of Ig light chains in the 
serum of patients and assessing the proliferation rate in 
bone marrow biopsies. Based on that and our previously 
reported potential association of intracellular Ig light 
chains with basal MET uptake (14), treatment-induced 
changes in intracellular Ig light chains as well as in 
proliferation were determined.
All three proteasome inhibitors uniformly reduced 
the proliferative activity of MM cell lines by 50–60% 
compared to untreated controls (p < 0.02) (Figure 3A). 
However, the extent of this reduction did not parallel the 
change in uptake of either MET or FDG (Supplementary 
Figure 1B).
Likewise, levels of intracellular Ig light chains were 
significantly (p < 0.02) lower in MM.1S and OPM-2 cells 
following drug exposure, but the extent of reduction of Ig 
levels and tracer uptake, respectively, did not correlate. 
In INA-6 cells Ig light chain levels only decreased 
after exposure to Iz (~50%), while Bz and Cz resulted 
in approximately 1.4-fold higher levels (Figure 3B, 
Supplementary Figure 1C).
Early assessment of response to Bz in CD138+-
plasma cells using MET or FDG
To validate our findings in a more physiological 
setting, we isolated primary CD138+-plasma cells from 
MM patients (see Supplementary Table 1 for patients’ 
characteristics), split the samples into four groups and 
analyzed radiotracer uptake: (i) untreated/ MET, (ii) 
untreated/ FDG, (iii) 24 h Bz/ FDG, (iv) 24 h Bz/ MET. 
In agreement with the results obtained in MM cell lines, 
addition of Bz decreased MET retention markedly in 6/7 
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cases (remaining sample: higher uptake in presence of 
Bz); in contrast, FDG uptake increased in 4/6 samples and 
decreased in only 2/6 (Figure 4A). In the 4 samples that 
contained enough cells for further FACS analyses, neither 
levels of intracellular immunoglobulin light chains nor 
expression of CD138 were impacted at this early time 
point (24 h drug exposure) (Figure 4B).
MET-PET reveals very early treatment response 
in vivo
As radiotracers underlie an in vivo metabolism 
which might impact their uptake by tumors, we 
investigated MET as well as FDG retention in Nod.Scid 
mice bearing MM.1S tumor xenografts before and 24 h 
after treatment with Bz. Prior to treatment, PET-imaging 
with MET, in clear contrast to FDG, resulted in high 
tumor-to-background ratios (median of mean TBR: MET 
3.98, range 1.1–8.0; FDG 1.92, range 0.7–5.8; n = 40; 
p < 0.02). Importantly, 24 h after Bz injection, tumor 
MET-uptake was reduced significantly by 30–79% (mean 
reduction in TBR to 55 ± 18%; median of mean TBR 2.55, 
range 0.8–4.5, p < 0.02; n = 17) compared to the uptake 
at baseline in the same mouse. In the control group TBRs 
increased to a mean of 125 ± 34% (median of mean TBR 
4.06, range 2.0–8.3, p = 0.432; n = 15) compared to the 
uptake at baseline in the same mouse.
Using FDG-PET, no differences between TBRs of 
control (mean increase in TBR to 144 ± 79%; median of 
mean TBR 2.22, range 1.3–6.1, n = 17) or treatment group 
(mean increase in TBR to 141 ± 66%; median absolute 
TBR 2.53, range 1.0–5.9, p = 0.897; n = 15) could be 
detected (Figure 5A, 5B, 5C). Interestingly, molecular 
analyses of tumors resected after the last PET-scan did not 
show clear differences but only a slight tendency in the 
treatment-group to less living cells, proliferative activity, 
intracellular immunoglobulin light chain levels or CD138 
expression (Figure 5D).
Figure 1: Monitoring response to proteasome inhibitors in MM cell lines using MET or FDG. Cells were treated for 48 h 
with either proteasome inhibitor or left untreated before intracellular radioactivity after incubation with MET (top) or FDG (bottom) was 
quantified using a gamma-counter. Relative uptake of background- and decay-corrected triplicate-samples was expressed as cpm per 1000 
cells (mean ± sem; n = 4).
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Early reduction in MET uptake correlates with 
improved survival
In a second line of experiments, xenografted 
mice received MET as well as FDG scans at baseline, 
24 h, at d8 (before third Bz administration) and at 
d15 (4 days after completion of one Bz therapy cycle) 
post-treatment initiation. All mice were followed up until 
death or a human end point was reached. Treatment with 
Bz significantly reduced tumor burden (Supplementary 
Figure 3A, 3B) and improved survival of mice (median 
34 days, range 30–39 days; compared to a median of 
15 days, range 7–30 days, in the control-group; p = 0.001) 
(Figure 6A).
Figure 2: Changes in tracer uptake upon proteasome inhibition are associated with CD138 cell surface levels. Flow 
cytometric quantification of the percent of CD138+ cells (percent of total; (A)), extent of CD138 expression (geometric mean fluorescent 
intensity, GeoMean; (B)) and percent CD138high and CD138low MM cells, respectively, (C) is shown as background-corrected means 
± standard deviation, related to that of untreated controls (n = 5). Asterisk indicate statistically significant differences (p < 0.02).
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In all treated mice, MET uptake was markedly 
reduced 24 h post-treatment initiation (see Figure 5). 
MET-tumor-uptake remained constant or decreased only 
slightly in consecutive scans on d8 and d15. In the control 
group TBRs progressively increased over time (Figure 
6B, top). In contrast, FDG scans revealed no discernible 
pattern and did not allow the separation in treatment-group 
and control (Figure 6B, bottom).
To investigate the impact of early reduction of MET-
retention, changes in tracer uptake were correlated to 
survival and tumor burden. Mice with reduced MET uptake 
24 h after treatment-initiation (cut-off: < 100% of TBR at 
baseline) had a significantly improved median survival of 
35 days (range 29–40d), compared to a median survival of 
17 days (range 9–26d) in those animals with unchanged or 
higher tracer-retention (p = 0.008) (Figure 6C). In contrast, 
FDG-PET did not correlate with survival: while mice with 
reduced FDG-retention (24 h) had a median survival of 
23 days (range 12–34d), mice with an increased uptake 
survived for a median of 26 days (range 16–36d; p = 0.497) 
(Figure 6D). Likewise, a reduced MET uptake, but not 
FDG uptake, 24 h after treatment-initiation correlated with 
a reduction in tumor burden after completion of one cycle 
bortezomib (d15; compared to baseline) (Supplementary 
Figure 3C). All mice with a reduced MET uptake at 24 h, 
a lower tumor burden at d15 and longer survival had been 
treated with bortezomib.
DISCUSSION
This study aimed at the in vivo validation of the 
radiolabeled amino acid MET as radiotracer and biomarker 
for MM focussing on early assessment of treatment 
response and outcome prediction in comparison to FDG.
In MM cell lines and primary cells, initial MET 
uptake was higher than that of FDG. Although proteasome 
inhibition resulted in a reduction of both MET and FDG 
retention, MET uptake of treated cells was higher than that 
of FDG as well. This is well in line with our previously 
published data reporting high MET retention in MM 
cells (14). It might, at least in part, be explained by the 
observation that addition of the protein synthesis inhibitor 
cycloheximide reduced retention of MET in MM cells 
but not of FDG suggesting that MET is not only taken 
up but also incorporated into newly synthesized proteins 
Figure 3: Treatment-induced alterations of further hallmarks of MM biology do not parallel changes in tracer-
uptake. (A) Relative proliferation rate as assessed by CFSE dilution (GeoMean; n = 5). (B) Intracellular levels of either λ- (MM.1S, 
OPM-2) or κ- (INA-6) immunoglobulin light chains were determined by FACS analysis (GeoMean) using anti-Ig λ-FITC- and anti-Ig 
κ-APC antibodies (n = 5). Background-corrected means ± standard deviation related to that of untreated controls are shown. Asterisk 
indicate statistically significant differences (p < 0.02).
Oncotarget8423www.impactjournals.com/oncotarget
(Supplementary Figure 4). By displaying relatively 
higher uptake in MM cells prior to and following 
treatment, MET might prove more sensitive in terms of 
detection of MM lesions per se and of changes in disease 
activity: visualization of MM manifestations with a low 
metabolism (usually missed by FDG) as well as of more 
subtle metabolic changes within a given lesion might be 
feasible using MET.
The proteasome inhibition-induced reduction in 
radiotracer uptake was correlated with alterations of other 
features of MM biology. We have already reported on a 
potential association of intracellular Ig light chains with 
initial MET uptake (14). In this series, extent of changes 
in radiotracer uptake and of reductions in cell proliferation 
or intracellular Ig light chains, respectively, could not be 
matched. However, CD138 expression on the cell surface 
showed a treatment-induced reversal of CD138high to 
CD138low MM cells which correlated with tracer uptake: 
the larger the reduction in tracer uptake, the lesser CD138 
at the cell surface. The implication of this observation is 
not fully understood. CD138 is known to be an important 
factor for bone marrow homing of MM cells ((15) and 
references therein). A decrease of CD138 levels might 
thus be a direct result of proteasome inhibition, thereby 
promoting tumor cell migration from the BM niche into 
the periphery where immunosurveillance is more effective 
(16,17).
Taken together, our in vitro data suggest superiority 
of MET to FDG regarding MM detection, monitoring 
of treatment response and a possible link to underlying 
tumor biology. Although FDG has been reported to be 
of prognostic value in therapy assessment (10,11,18,19), 
given our data, MET seems to be a more versatile marker.
This notion is further corroborated by in vivo 
experiments in xenotransplanted Nod.Scid mice. Well 
in line with our findings in MM cell lines and primary 
Figure 4: Assessing early response to Bz in CD138+-plasma cells using MET or FDG. (A) CD138+-plasma cells from 
individual patients were or were not treated with Bz for 24 h, subsequently incubated with either FDG or MET for 60 min and intracellular 
radioactivity was quantified using a gamma-counter. Relative uptake of background- and decay-corrected samples was expressed as mean 
cpm per 1000 cells. Horizontal lines indicate the median in each group. The table gives the uptake values (cpm/1000 cells) for each patient. 
(B) Cell surface expression of CD138 and intracellular levels of Ig light chains in control and treated primary MM cells are shown as 
GeoMean (n = 4).
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Figure 5: MET-PET reveals very early treatment response in vivo. MM.1S tumors in Nod.Scid mice were imaged at baseline 
and 24 h after administration of Bz using MET- and FDG-PET, respectively. (A) Coronal views of an exemplary mouse. (B) Mean TBRs of 
FDG and MET at baseline (bl), in the control (ctrl) and treatment (Bz) group. (C) Relative change in tracer-uptake by tumors (mean TBR) 
in individual mice 24 h post treatment initiation compared to baseline. (D) FACS analyses evaluating dead cells (top left), CD138 (top 
right) and intracellular Ig light chain (bottom right) expression. Proliferation (bottom left) was assessed histologically by Ki-67 staining 
on paraffin embedded sections. Horizontal lines indicate the median in each group. Asterisk indicate statistical significance (p < 0.02). 
Differences in (D) are not statistically significant.
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Figure 6: Early reduction in MET uptake correlates with improved survival. (A) Kaplan-Meier-curve of animals treated 
with bortezomib (d1-4-8-11; n = 7; green) and control group (n = 8; blue). (B) Tumor-to-background ratios of MET (top) and FDG 
(bottom) uptake in treatment (dashed lines)- and control (solid lines) group at baseline, 24 h, 8d and 15d after treatment initiation. 
Correlation of changes in MET (C) and FDG (D) uptake 24 h post treatment initiation with survival (green, responders; blue, non-
responders).
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cells ((14) and Figure 1), μPET-imaging with MET 
prior to treatment resulted in much higher tumor-to-
background ratios underlining its superior sensitivity in 
comparison to FDG. Most importantly, treatment and 
control groups could clearly be differentiated with MET 
but not with FDG. Only MET was capable to detect very 
early tumor response as early as 24 h after initiation of 
proteasome inhibitor treatment; neither FDG-uptake nor 
any other tumor marker (Ki-67/ proliferation, CD138, Ig 
light chains) was affected at that time. As MET intensity 
robustly dropped by ≥ 30% the early reduction of TBRs 
observed here is likely to reflect a true response (20–22). 
In addition, a metabolic response in 24 h PET-imaging 
compared to baseline significantly correlated with 
prolonged survival and reduced tumor burden. Thus, MET 
not only seems to improve MM diagnosis and therapy 
monitoring but also to be a radiotracer providing predictive 
potential regarding response (discrimination of responders 
and non-responders) and outcome. The former notion is 
also supported by other studies demonstrating a clinical 
value of MET-PET with an equal or greater number of MM 
lesions detected by MET vs. FDG (23–25). Interestingly, 
a very recent study demonstrated a correlation of large 
amino acid transporter 1 (LAT1) expression on patient-
derived MM cells with increased proliferative activity of 
these cells and a worse prognosis (26). LAT1 is the major 
transmembrane-transporter for MET and an association 
between LAT1 expression and 11C-MET uptake has been 
shown in gliomas (27). Thus, it is appealing to speculate 
about a potential connection of MET-uptake and patient 
prognosis. In translation to the human disease, very early 
response assessment might impact on patient management 
by termination of ineffective treatment regimens, thereby 
optimizing anti-myeloma drug activity and minimizing 
futile adverse effects. Additionally, early MET-PET might 
indicate subjects with an overall very good response but 
a single or few remaining lesions with persisting high 
metabolism after one week of treatment. These patients 
might be candidates for additional local treatment such 
as radiation therapy, enabling local disease control. 
Thus, very early PET imaging using radiolabeled amino 
acids such as MET would establish a novel approach for 
treatment individualization, allowing for therapy initiation 
and adjustments earlier than any other existing method, 
even outperforming analysis of free light chains (28). 
A pilot trial investigating the performance of very early 
treatment response MET-PET in patients with MM is 
highly warranted to further investigate the usefulness of 
PET imaging in this regard. Potential drawbacks of the 
amino acid tracer concerning reduced sensitivity within 
the liver and pancreas due to high physiologic uptake 
can be neglected, given the very rare involvement of 
these organs in this disease and the broad availability of 
combined PET/CT imaging. Access to an on-site cyclotron 
could represent a limiting factor for the widespread use of 
11C-MET PET in daily clinical practice.
Concluding, our results suggest that MET is superior 
to FDG in detecting MM manifestations, in assessing 
response to anti-MM treatment and might provide a link 
to underlying tumor biology. Monitoring of response at 
a very early time seems feasible exclusively with MET-
PET. Moreover, early changes in MET retention have 
predictive potential regarding response and survival. Thus, 
MET uptake might serve as a biomarker for MM, opening 




All experiments involving human material were 
approved by the ethics committee of the University 
of Wuerzburg (#192/12). Bone marrow biopsies from 
patients diagnosed with MM were taken after obtaining 
informed written consent from each patient.
Animal studies were performed in agreement 
with the Guide for Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH 
Publication No. 85–23, revised 1996) and in compliance 
with the German law on the protection of animals (license 
55.2–2531.01–65/12).
Cell culture and treatment
The human myeloma cell lines INA-6 (provided by 
Dept. of Hematology, University Hospital Wuerzburg), 
OPM-2 (DSMZ no. ACC50) and MM.1S (ATCC no 
CRL-2974) were cultured and tested for contamination 
with mycoplasma as described previously (14). Cell line 
identity was confirmed at the DSMZ (July 2013). Where 
indicated, cells were treated for 48 h with bortezomib 
(Velcade®), ixazomib (MLN9708) or carfilzomib 
(Kyprolis®). All drugs were obtained from Selleckchem 
(Munich, Germany). Concentrations used were established 
by adding various amounts of the respective compound to 
the cells and assessing the extent of cell death induced. For 
treatment, the respective concentration resulting in 50% 
dead cells was chosen (Table 1):
For inhibition of protein synthesis, cyclohexamide 
(Sigma-Aldrich, Taufkirchen, Germany) was used at a 
concentration of 50 μg/mL for 2 h.
Table 1: Concentration of drugs used for the 
treatment of myeloma cell lines
INA-6 MM.1S OPM-2
bortezomib 2.5 nM 2.0 nM 2.5 nM
ixazomib 28.5 nM 36 nM 20 nM
carfilzomib 6.0 nM 6.0 nM 7.0 nM
Oncotarget8427www.impactjournals.com/oncotarget
Isolation of CD138+-plasma cells
CD138+-plasma cells were isolated from bone 
marrow aspirates of patients diagnosed with MM as 
previously described (14). Uptake experiments were 
performed as described below but with 100 000 cells/
sample and incubation with 1*106 counts per minute 
(cpm) of either radiotracer for 60 min. Where indicated, 
2.0 nM bortezomib was added to the sample 24 h prior to 
the uptake study.
Flow cytometric analyses
Single cell suspensions were stained with 
fluorochrome conjugated antibodies against hCD138+-
APC (Syndecan; clone B-B4), anti-hIg kappa light 
chain-APC (clone IS11–24D5) or anti-hIg lambda 
light chain-FITC (clone IS7–24C7; all antibodies from 
Miltenyi, Bergisch-Gladbach, Germany) and analyzed 
with a BD FACSCalibur flow cytometer using the BD 
CellQuest software (Beckton Dickinson, Heidelberg, 
Germany) according to the manufacturer’s instructions.
Cell proliferation assay (cell culture)
Proliferation was assessed by labeling cells with 
1 μM carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Invitrogen, Karlsruhe, Germany) in 3% FCS/PBS 
for three minutes at room temperature. Cells were seeded 
at a density of 1*105 cells/ well on a 96-well plate, allowed 
to grow for 48 h and were then harvested and resuspended 
in 300 μl propidium iodide (PI) solution (2.5 μg PI 
(Sigma-Aldrich, Taufkirchen, Germany)/ 3% FCS/PBS). 
Proliferation of living cells was measured by FACS in 
the FL-1 channel as the decrease in CFSE fluorescence 
intensity.
Ki-67 staining of paraffin embedded tumor tissue
Tumors were resected and immediately embedded 
in Tissue-Tek® OCT Compound (PLANO, Wetzlar, 
Germany) for cryostat sectioning (Microm HM-500 M 
Cryostat; Thermo-Scientific, Dreieich, Germany). 6 μm-
sections were fixed with absolute acetone, blocked with 
0.2% BSA (Sigma-Aldrich, Taufkirchen, Germany)/ 2% 
donkey serum (abcam, Cambridge, UK)/ PBS and stained 
with rabbit-anti-Ki-67 antibody (dilution 1:100; clone 
SP6; abcam, Cambridge, UK) for 1 h. An Alexa Fluor® 
555 donkey-anti-rabbit IgG antibody (dilution 1:800, 
1 h; Molecular probes, Darmstadt, Germany) was used 
for detection. Cell nuclei were stained with dapi (dilution 
1:1000, 10 min; Molecular probes, Darmstadt, Germany). 
Slides were coverslipped with VECTASHIELD® 
Mounting Medium (Biozol, Eching, Germany). For 
analysis, all cells in a field of view at 40x magnification 
were counted using Image J Software (http://imagej.
nih.gov/ij/) and the percentage of proliferating (Ki-67 
positive) cells was determined. In total, five fields of view 
were evaluated and mean and standard deviation were 
calculated.
CD138 (Syndecan) ELISA
CD138 released into medium was quantified by 
sandwich-ELISA using the Syndecan (CD138) Human 
ELISA Kit (abcam, Cambridge, UK) according to the 
manufacturer’s instructions. Samples were measured 
undiluted and in duplicates.
Synthesis of 18F-FDG (FDG) and 11C-MET 
(MET)
Radiopharmaceuticals were produced in-house with 
a 16 MeV Cyclotron (GE PETtrace 6; GE Healthcare, 
Milwaukee,WI, USA) as described previously (14).
Cellular uptake experiments
Sub-confluent cell cultures were harvested and 
adjusted to a concentration of 400 000 cells/ 500 μL 
PBS per sample. Radioactive substances were diluted 
to 1*106 cpm/ 50 μL PBS. After addition of 1*106 cpm, 
samples were incubated for various time intervals up to 
120 min at 37°C. Tracer uptake was stopped by incubation 
on ice, followed by washing twice with PBS to remove 
residual radioactivity. Intracellular radioactivity was 
quantified using a semi-automated gamma-counter 
(Wallac 1480-Wizard, Perkin Elmer, Rodgau, Germany). 
All samples were measured in triplicates. Background 
activity- and decay-corrected data were expressed as cpm 
per 1000 cells.
Animal studies
NOD.CB17-Prkdcscid/NCrHsd mice were bred at the 
animal facility at the Center of Experimental and Molecular 
Medicine (ZEMM) of the University of Wuerzburg. 
Animals received water and food ad libitum; mice were 
housed in filter-top cages at ambient temperature with a 
light/dark cycle of 12/12 h. Pathogen status was assessed 
according to FELASA B protocol on a regular basis. 5*106 
MM.1S cells in 100 μl PBS were injected subcutaneously 
into the flank of approximately 8 week old animals. Mice 
were visually inspected daily and tumor growth was 
monitored using a shifting caliper. Imaging experiments 
were initiated when tumor size reached 100–200 mm3. Mice 
(n = 40) were randomized into control (0.9% NaCl) and 
treatment groups (n = 20 each; group sizes corresponded 
to the biometrical calculations provided in the relevant 
animal license). The latter received 1 μg bortezomib/g 
body weight in 100 μl 0.9% NaCl intraperitoneally at day 
1, 4, 8 and 11. All mice received a PET-examination with 
MET, followed (4–5 h later) by a scan with FDG at baseline 
(day 0) and 24 h after treatment-initiation. Where indicated, 
Oncotarget8428www.impactjournals.com/oncotarget
MET and FDG scans were repeated at day 8 and day 15. 
Radiotracers (7–9MBq/ mouse) were injected into the tail 
vein of anesthetized (2% isoflurane; Abbott, Wiesbaden, 
Germany) animals using a veterinary anesthesia system 
(Vetland Medical, Louisville, KY, USA). For MET-PET, 
scanning was initiated 5 min post tracer-injection and 
lasted for 10 min; FDG images were acquired 60 min post-
injection for 15 min. Owed to the short half-life of 11C-MET 
(20 min), acquisition time for MET-PET was shortened to 
10 min to allow analysis of all mice in a given experimental 
cohort with the same batch of MET. Tumor lesions were 
imaged using a small-animal PET scanner (Inveon; 
Siemens Medical Solutions, Erlangen, Germany) and 
images were reconstructed using ordered subset expectation 
maximization 2D (OSEM 2D) algorithm. Mean tumor-to-
background ratios (TBR) were determined by drawing a 
volume of interest (VOI; 3×3×3 pixels) around individual 
tumor lesions and healthy soft tissue in the contralateral 
flank (background) using ‘A Medical Image Data Analysis 
Tool’ (AMIDE)-software (http://amide.sourceforge.net/). 
Background contrast for MET and FDG was similar (MET: 
median 49346 AU; FDG: median 42703 AU).
Statistical analysis
Statistical analyses were performed using PASW 
Statistics software (version 22.0; SPSS, Inc. Chicago, IL) 
or Microsoft Excel. Quantitative values were expressed 
as mean ± standard deviation or median and range as 
appropriate. Comparisons of related metric measurements 
were performed using Mann-Whitney-U test. Survival 
probabilities were calculated according to the Kaplan-
Meier method and the log-rank test was used for statistical 
comparison of survival curves between independent 
subgroups. All statistical tests were performed two-sided 
and a p-value < 0.05 was considered to indicate statistical 
significance.
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